Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece.

Neurol Ther · 2022 · PMC9338205 · PMID 35829919

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Primary Outcome: Quality of Life The mean MSIS-29 total score improved slightly both at 12 and 24 months from the BL value of 48.3 ± 16.7 (mean ± SD), though the changes did not reach statistical significance (Fig. 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.